BioNTech Sees Unusually Large Options Volume (NASDAQ:BNTX)

BioNTech SE (NASDAQ:BNTX) was the recipient of some unusual options trading on Tuesday. Stock traders purchased 4,599 call options on the stock. This represents an increase of approximately 58% compared to the typical daily volume of 2,906 call options.

BioNTech Trading Up 5.2 %

BNTX stock traded up $6.31 during trading on Tuesday, hitting $126.52. The company had a trading volume of 679,224 shares, compared to its average volume of 547,926. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The stock has a market cap of $30.33 billion, a PE ratio of -60.25 and a beta of 0.18. The business has a 50-day moving average of $113.47 and a 200-day moving average of $102.49. BioNTech has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.73 EPS. Research analysts predict that BioNTech will post -3.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

BNTX has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft increased their price target on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. TD Cowen lowered their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a research report on Tuesday, November 5th. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the stock from $90.00 to $137.00 in a research report on Friday, November 8th. Berenberg Bank assumed coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price on the stock. Finally, Canaccord Genuity Group raised their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a report on Wednesday, November 27th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $140.76.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baillie Gifford & Co. increased its holdings in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after purchasing an additional 31,773 shares in the last quarter. FMR LLC increased its position in BioNTech by 797.8% in the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after buying an additional 5,598,190 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock valued at $47,734,000 after acquiring an additional 24,426 shares during the period. Fred Alger Management LLC bought a new stake in shares of BioNTech in the third quarter valued at approximately $59,485,000. Finally, DekaBank Deutsche Girozentrale raised its holdings in BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock valued at $56,886,000 after acquiring an additional 53,800 shares during the period. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.